-
Dovitinib and ERK: Designing Better Cancer Assays
2026-08-23
Dovitinib (TKI-258) offers a powerful way to interrogate receptor tyrosine kinase and downstream ERK–STAT signaling in cancer models. This article connects its multitarget profile with IFNγ-driven melanoma apoptosis to improve mechanistic assay design beyond simple viability measurements.
-
Sabutoclax Workflows for Apoptosis Assays
2026-08-22
Sabutoclax is a membrane-permeable pan-Bcl-2 inhibitor for dissecting anti-apoptotic dependence across cancer models. This guide connects concentration-response testing with separate measurements of growth inhibition and cell killing, improving interpretation in vitro and during xenograft translation.
-
PreScission Protease for Nuclear Protein Workflows
2026-08-21
PreScission Protease combines sequence-defined HRV 3C protease activity with low-temperature processing for cleaner fusion-tag removal. This article translates that capability into practical workflows for soluble recombinant proteins, dKeap1–lamin Dm0 interaction studies, and troubleshooting-sensitive nuclear assays.
-
NSC 87877: Reliable Shp2 Inhibitor Workflows
2026-08-20
Learn how NSC 87877 (SKU A4544) can support reproducible Shp2 pathway experiments, from EGF-induced Erk1/2 signaling to viability and cytotoxicity assays. This scenario-based guide separates biochemical potency from cellular response and provides practical formulation, storage, and vendor-selection guidance.
-
M344: Practical HDAC Inhibitor Workflows
2026-08-20
M344 is a cell-permeable histone deacetylase inhibitor for linking chromatin acetylation to proliferation, differentiation, apoptosis, radiation response, and viral latency. This workflow-focused guide covers dose selection, assay controls, solubility, model-specific applications, and troubleshooting for reproducible in vitro and ex vivo studies.
-
Alfuzosin HCl: From Receptor Signal to Assay
2026-08-19
Explore how Alfuzosin HCl links α1-adrenergic pharmacology with gastroretentive formulation science and assay design. This evidence-led guide translates MRI-verified gastric retention into practical decisions for benign prostatic hyperplasia research.
-
PP2A, Autophagy, and Candida Biofilm Resistance
2026-08-19
The reference study identifies protein phosphatase 2A, particularly its PPH21 catalytic subunit, as a regulator of autophagy-linked biofilm formation and antifungal resistance in Candida albicans. By combining PPH21 deletion, rapamycin-mediated autophagy activation, molecular readouts, and an oral infection mouse model, the work connects Atg13 phosphorylation and Atg1 activation with treatment response.
-
ECL Western Blotting Substrate Guide
2026-08-18
ECL Western Blotting Substrate (SKU K2187) is a luminol-based, nonradioactive horseradish peroxidase detection reagent for chemiluminescent Western blot imaging. It is intended for HRP immunoblots using X-ray film or CCD cameras, not for fluorescent or radioisotopic detection workflows.
-
TRAP-1 Reactivates p53Y220C by Induced Proximity
2026-08-18
The preprint reports TRAP-1, a chemical inducer of proximity that brings mutant p53Y220C into a ternary complex with BRD4 and restores transcription of p53-responsive genes. In pancreatic cancer cell models, this mechanism rapidly increased p21 and other target genes while limiting cell growth, highlighting induced proximity as an alternative to simple mutant-protein stabilization.
-
Dacomitinib: Designing Mechanism-Resolved Assays
2026-08-17
Dacomitinib (PF-00299804) is an irreversible pan-HER inhibitor with a distinctive value in pathway-resolved cancer research. This guide explains how to separate ErbB signaling, apoptosis, cell-cycle arrest, and ferroptosis-related mitochondrial phenotypes when building translational assays.
-
Promethazine HCl: Designing Better Immune Assays
2026-08-17
Promethazine HCl is more than a histamine H1 antagonist: it is a useful probe for separating receptor pharmacology from ROS-, lysosome-, and autophagy-dependent macrophage responses. This article translates recent phenothiazine research into a rigorous assay-design framework for inflammation research.
-
Angiotensin (1-7): From Proteolysis to Precision Assays
2026-08-16
Angiotensin (1-7) is more than a Mas receptor agonist: its biological meaning depends on how it is generated and measured. This article connects microbial angiotensin processing with pathway-aware assay design and research use of the Asp-Arg-Val-Tyr-Ile-His-Pro peptide.
-
Removing Pollen Interference from EEM Hazard Classification
2026-08-15
Zhang and colleagues show that pollen can distort excitation–emission matrix fluorescence classification of hazardous biological substances, but that spectral transformation can substantially reduce this interference. Their random forest workflow, particularly when paired with fast Fourier transform processing, provides a practical framework for more reliable bioaerosol screening.
-
LRRC8A–Caveolin-1 Signaling in PDAC Growth
2026-08-14
The reference study identifies a cholesterol-dependent LRRC8A–Caveolin-1 complex that links cell-volume regulation with KRAS/EGFR signaling, ribosome biogenesis, and proliferative expansion in pancreatic ductal adenocarcinoma. Its integrated genetic, pharmacological, organoid, xenograft, and proteomic experiments position this membrane axis as a mechanistic vulnerability and provide a framework for studying biosynthetic growth in PDAC.
-
CBD, Orofacial Inflammatory Pain, and Pain Affect
2026-08-14
A 2026 Brain Research Bulletin study shows that cannabidiol (CBD) can reduce inflammatory nociception while improving affective and cognitive abnormalities in mouse pain models. Its main contribution is a multi-level mechanism linking peripheral CB2 signaling, central CB1-associated endocannabinoid changes, and serotonin dynamics in the central amygdala.